NCT00805142 - Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

PainCancer

Interventions

DRUG

Tapentadol PR

Tapentadol PR tablets will be administered orally twice daily initiated at dose of 25 mg. Dose will be adjusted as per Investigator's discretion. Maximum dose limit is 500 mg per day. Total duration of treatment is 19 days.

Trial Locations (21)

Unknown

Chiba

Chikushino-shi

Fukuoka

Himeji

Hirosaki

Ichinomiya

Ikeda

Iwakuni

Kobe

Kochi

Kyoto

Nishinomiya

Ohta

Osaka

Sapporo

Sasebo

Shizuoka

Sonogishukugō

Tokyo

Toyonaka

Utsunomiya